CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director. Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology. He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr….
News and Press
ProteinLogic has patent granted in USA and EU, files 2nd patent Company expands presence in the TB biomarker space
CAMBRIDGE, UK (2019-01-17) ProteinLogic (PL), the biomarker discovery and exploitation company, has received approval for granting of its first patent in biomarkers for the diagnosis of Tuberculosis in the USA and the EU. At the same time, the company has filed a 2nd patent in the same space. This new patent allows the company to…
ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director
CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director. Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership…
ProteinLogic Presents at McGill Summer Institute on Advanced TB Diagnostics
CAMBRIDGE, UK (2018-06-25) ProteinLogic (PL), the biomarker discovery and exploitation company, was invited to present its latest findings at the 8th McGill University’s Summer Institute for Advanced TB Diagnostics, held on the 18th-22nd of June 2018, in Montreal, Canada. CEO Nicolas Huber presented PL’s exciting developments in TB diagnosis to participants from the global TB…
ProteinLogic Joins BIVDA
CAMBRIDGE, UK (2018-06-06) – ProteinLogic the biomarker discovery and exploitation company has become an affiliate member of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry and has represented manufacturers and distributors of IVD products for over…
ProteinLogic Presents At Bio€quity 2018, Ghent, Belgium
CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies. ProteinLogic was invited to present to a panel of investors and…
ProteinLogic At BioTrinity 2018, London, UK
CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players. The event included panel discussions of significant interest, especially regarding market access globally, the…
ProteinLogic Appoints Darleen Welford as VP of Regulatory Affairs and Quality Assurance
CAMBRIDGE UK (2018- 03- 05) – ProteinLogic, the biomarker discovery and exploitation company has appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring valuable global regulatory expertise, and to further the company’s RA strategy. Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and…
ProteinLogic Appoints Dr Nicolas Huber as Chief Executive Officer
CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer. Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past…
48th Union World Conference on Lung Health in Guadalajara, Mexico
ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017. The conference theme was ‘Accelerating Toward Elimination’. There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with…